Testosterone Injections Do Not Cause Degenerative Disc Disease in Trans Males
Based on current evidence, there is no established causal link between testosterone injections and degenerative disc disease (DDD) in transgender males. The available guidelines and research do not identify DDD as a recognized complication of gender-affirming hormone therapy (GAHT) with testosterone.
Evidence from Guidelines
The most recent comprehensive guidelines on transgender medicine 1 extensively detail the known risks of testosterone therapy in trans men, which include:
- Cardiovascular effects: Increased blood pressure, hematocrit, triglycerides, and LDL cholesterol with decreased HDL 1
- Hematologic risks: Erythrocytosis requiring monitoring of complete blood counts 1
- Bone health concerns: Risk related to hypogonadism if testosterone is inadequately dosed 1
- Metabolic changes: Potential impacts on lipid profiles and insulin sensitivity 2
Notably absent from these comprehensive risk assessments is any mention of degenerative disc disease or spinal pathology. The 2009 Endocrine Society guidelines 3 similarly outline monitoring parameters for testosterone therapy without identifying DDD as a concern.
What the Research Actually Shows
Recent research on sex hormones and disc health suggests the opposite relationship:
- Testosterone may be protective: Studies demonstrate that sex hormones including testosterone can attenuate pro-inflammatory gene expression in nucleus pulposus and annulus fibrosus cells 4
- Anti-inflammatory effects: Both dihydrotestosterone and estrogen decrease proinflammatory cytokine release in intervertebral disc cells 4
- Age is the primary factor: The most significant risk factor for disc degeneration is age, not hormonal therapy 5
The research on sex hormones and DDD 6 discusses estrogen-deficient states as potentially problematic for disc health, but does not implicate testosterone supplementation as causative of degeneration.
Clinical Implications
When evaluating a trans male patient with back pain or suspected DDD:
- Do not attribute disc disease to testosterone therapy based on current evidence
- Evaluate for standard DDD risk factors: Age, obesity, smoking, physical activity level, occupational factors 7
- Continue appropriate testosterone monitoring as outlined in guidelines: hemoglobin/hematocrit, liver function, lipids, blood pressure 1, 3
- Address modifiable cardiovascular risk factors that testosterone may influence, as these are the documented concerns 8, 2
Important Caveats
While testosterone does not cause DDD, trans men on GAHT do experience:
- Increased lean muscle mass and strength 1, which could theoretically alter biomechanical loading patterns
- Weight gain and changes in body composition over time 2, which are established DDD risk factors through general mechanisms
- Inflammatory markers elevation 8, though the disc-specific research suggests local anti-inflammatory effects 4
These indirect factors should be managed through standard preventive care: weight management, smoking cessation, and physical activity optimization 1.